Targeting iRhom2 for better treatment of autoimmune diseases
SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Improving autoimmune disease therapies is the central aspiration of SciRhom. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in late 2016 through a collaboration between scientists from academia and scientists with profound experience in antibody development. Two patent families cover anti-iRhom2 antibodies and the iRhom2-target epitope. To date, SciRhom has secured about EUR 7 million in seed funding from the High-Tech Gruenderfonds (HTGF), the Hospital for Special Surgery (HSS) and private investors.
Dr. Jens Ruhe
Chief Executive Officer, Managing Director
T +49 (0)89 614 2412 31
Jens co-founded SciRhom GmbH, formerly SciMab GmbH, in late 2016. He has a longtime experience in signal transduction biology and therapeutic antibody development. As co-founder of U3 Pharma GmbH, Jens was involved in new drug target identification, before he joined Prof. Dr. Axel Ullrich to establish a laboratory and cancer genome project at the Institute of Medical Biology (IMB), Agency of Science, Technology and Research (A*STAR) in Singapore. After the acquisition of U3 Pharma by Daiichi Sankyo, Jens served as Authorized Officer and Director Research & Development. In global teams, he was in charge of preclinical development of early to clinical stage antibody projects, including U3 Pharma’s Patritumab lead program. Jens was trained in genetics and immunology at the University of Konstanz, and obtained his PhD in Molecular Biology from Prof. Dr. Axel Ullrich at the Max Planck Institute of Biochemistry, Martinsried.
Dr. Matthias Schneider
Chief Scientific Officer
T +49 (0)89 614 2412 32
Matthias co-founded SciRhom GmbH, formerly SciMab GmbH, in late 2016. He is a biologist with an extensive experience in biomarker identification and antibody development. Being with U3 Pharma/Daiichi Sankyo from 2008 to mid 2016, he advanced to the preclinical head of the Patritumab lead program. Matthias studied biology at the University Würzburg and earned his PhD in molecular biology in the lab of Prof. Dr. Axel Ullrich at the Max-Planck-Institute of Biochemistry, where he gained deep insights in GPCR/EGF-Receptor crosstalk in oncology.
Prof. Carl Blobel
Dr. Blobel is Professor of Medicine (Rheumatology Division) and of Physiology, Biophysics and Systems Biology at Weill Cornell Medical College, and Chairman of the Arthritis and Tissue Degeneration Program at the Hospital for Special Surgery. He received an MD degree from the Justus-Liebig University in Giessen, Germany and a PhD degree in Biochemistry from the University of California, San Francisco. Dr. Blobel has pioneered studies on the newly discovered iRhom1/2 as crucial upstream regulators of ADAM17-dependent EGFR and TNFα-signaling. His work has led to a better understanding of how iRhoms and ADAM17 can promote autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus and EGFR-dependent pathologies such as cancer.
Prof. Axel Ullrich
From 1988 to 2016 Prof. Ullrich was the Director of the Molecular Biology Department at the Max Planck Institute of Biochemistry in Martinsried, Germany. His groundbreaking research in the field of signal transduction allowed essential insights into the pathophysiological mechanisms of major human diseases such as diabetes and cancer. Amongst others, Prof. Ullrich’s research activities led to the development of genetically engineered human insulin for the treatment of diabetes, as well as Herceptin, the first targeted antibody-based cancer therapy. With more than 60,000 citations he is one of the most cited scientists over the past 25 years. Axel Ullrich has co-founded six biotech companies throughout his career and was one of the first employees of Genentech. He has been awarded numerous prizes, and most recently was honored with the 2019 Lasker Award.
TACE (TNF-alpha converting enzyme or ADAM17) is an essential regulator of several major signaling pathways, including TNF-alpha and EGFR (epidermal growth factor receptor) signaling (1). Therefore, TACE controls both physiological and pathophysiological processes. Inhibition of TACE could provide therapeutic benefits by blocking several pro-inflammatory pathways at the same time, but is also expected to cause severe side effects, since patients lacking TACE are prone to skin infections and intestinal lesions (2). These side effects can be explained by the protective role of TACE-dependent activation of the EGFR, mainly through processing of the EGFR-ligand TGF-alpha (3,4). The recent discovery that TACE-dependent release of TNF-alpha and other pro-inflammatory mediators from immune cells is regulated by iRhom2 (RHBDF2, Rhomboid family member 2, refs. 5-7) provided an exciting new opportunity to target the pro-inflammatory activities of TACE, while preserving its protective functions in the skin and intestine, which can be maintained by the related iRhom1 (6,8). iRhom2 knock-out mice are protected in mouse models for RA (6,9) and glomerulonephritis caused by Systemic Lupus Erythematosus (10) but are normal and healthy and do not develop the skin or intestinal defects seen in mice and patients that are deficient in TACE (5-7). Thus, targeting iRhom2 provides the unique and exciting opportunity to selectively target the pathogenic and pro-inflammatory functions of TACE without causing the severe side effects expected from blocking TACE itself. A major hurdle towards translating this concept into the clinic has been cleared through the identification of function-blocking antibodies against iRhom2. These antibodies are now ready for preclinical and clinical development, with the ultimate goal of providing superior treatment options to currently existing inhibitors of TNF-alpha signaling.
- Blobel CP. Nature Rev Mol Cell Bio. 2005;6:32-43.
- Blaydon DC et al., N Engl J Med. 2011;365(16):1502-1508.
- Chalaris A et al., J Exp Med. 2010;207(8):1617-1624.
- Franzke CW et al., J Exp Med. 2012;209(6):1105-1119.
- McIlwain DR et al., Science. 2012;335(6065):229-232.
- Issuree PD et al., J Clin Invest. 2013;123(2):928-932.
- Adrain C et al., Science. 2012;335(6065):225-228.
- Li X et al., Proc Natl Acad Sci U S A. 2015;112(19):6080-6085.
- Buckland J., Nature Rev Rheumatol. 2013;9(3):136.
- Qing X et al., J Clin Invest. 2018;128(4):1397-1412.
T +49 (0)89 614 2412 30
Am Klopferspitz 19
November 5, 2019
SciRhom initiates first-in-class antibody development program to treat major autoimmune diseases
Bench to bedside research provides a new business opportunity: Newly discovered antibodies against iRhom2 block several pro-inflammatory pathways simultaneously, promising significant improvement over current autoimmune therapies.
Munich, Germany, November 5, 2019 – SciRhom GmbH, a therapeutic antibody company, announced today the development of first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
iRhom2 is a protein that controls the tumor necrosis factor-alpha-convertase (TACE; also known as ADAM17), a set of molecular scissors that activates several crucial signaling pathways, including TNF-alpha (tumor necrosis factor-alpha) and other disease-related signaling 1-6. Blocking TACE, however, raises major concerns about side effects, as TACE-deficient patients show severe skin and intestinal defects 7. In contrast, antibodies against iRhom2 would have the unique advantage over TACE-targeted therapies of simultaneously blocking several TACE-dependent disease-associated pro-inflammatory pathways without causing lesions in the skin and intestinal barrier. Moreover, antibodies against iRhom2 are expected to be superior over anti-TNF-alpha biologics due to their ability to interfere with other important pro-inflammatory pathways. This concept has been validated using iRhom2 knockout mice, which are normal and healthy, but are protected from Rheumatoid Arthritis (RA) and glomerulonephritis caused by Systemic Lupus Erythematosus 8,9.
These proof-of-concept studies were primarily conducted by Professor Dr. Carl Blobel, co-founder of SciRhom and pioneer of the TACE/ADAM17 field, and his colleague, Professor Dr. Jane Salmon. Prof. Blobel is Program Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery (HSS) in New York, USA, one of the world’s top-ranking academic medical centers in Rheumatology and musculoskeletal health.
From these promising results, SciRhom has identified iRhom2-specific antibodies that block TNF-alpha release by TACE and is currently advancing the preclinical development of its first-in-class anti-iRhom2 antibodies towards IND-enabling studies. SciRhom was founded and is led by a highly experienced management team with an excellent track record in antibody drug development that consists of Dr. Jens Ruhe, co-founder of U3 Pharma and former Director R&D at U3 Pharma / Daiichi Sankyo and Dr. Matthias Schneider, previously Preclinical Head of the Patritumab lead program at U3 Pharma / Daiichi Sankyo. In addition to Professor Dr. Carl Blobel, the co-founders of SciRhom are Professor Dr. Axel Ullrich, biotech pioneer, former Director at the Max Planck Institute of Biochemistry and recent recipient of the prestigious Lasker Award, Dr. Andreas Jenne, serial biotech entrepreneur, and HSS. To date, SciRhom has secured about EUR 7 million in seed funding from the High-Tech Gruenderfonds (HTGF), HSS and private investors.
“We are delighted about the excellent and close collaboration with Professor Blobel and HSS, the outstanding work of our team and the strong support by all of our shareholders. Our joint efforts led to the successful generation of first-in-class antibodies against the novel and highly promising target iRhom2, which are protected by the filing of two strong patent applications,” said Dr. Jens Ruhe. “Based on the novel mechanism of action, this approach promises to be a significantly more effective and much safer therapy for autoimmune disease patients. Backed by the clinical excellence of HSS in Rheumatology we are now thrilled to take our anti-iRhom2 antibodies into the clinic as expediently as possible.”
“With the launch of SciRhom we are fulfilling a vision our teams have pursued for more than a decade. We are excited by the opportunity to advance our bench to bedside research into clinical development to provide novel targeted treatment options for patients with debilitating and life-threatening autoimmune diseases,” commented Prof. Dr. Carl Blobel. “iRhom2 provides a unique and completely new approach for the inhibition of several disease-causing pathways simultaneously, including TNF-alpha signaling. We have identified antibodies with a unique profile, showing potent inhibition of iRhom2/TACE without affecting TACE-dependent pathways that are essential for normal physiology. We hope that these efforts will ultimately give clinicians superior treatment options to improve the quality of life of patients.”
TACE (TNF-alpha converting enzyme or ADAM17) controls several major signaling pathways, including TNF-alpha signaling 1,2,5,6. TACE has therefore been considered a potential target for blocking pro-inflammatory pathways, but blocking TACE could cause severe side effects, such as skin and intestinal lesions 7. The recent discovery that iRhom2 (inactive Rhomboid 2, RHBDF2) simultaneously regulates the TACE-dependent release of TNF-alpha and of other pro-inflammatory molecules from immune cells provided the exciting opportunity to target the pro-inflammatory activities of TACE, while preserving its protective functions 3,4,8,9. A major hurdle to translating this concept into the clinic has now been cleared through the identification of function-blocking antibodies against iRhom2.
About SciRhom GmbH
SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Improving autoimmune disease therapies is the central aspiration of SciRhom. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in late 2016 through a collaboration between scientists from academia and scientists with profound experience in antibody development. Two patent families cover the anti-iRhom2 antibodies and iRhom2-target epitope. To date, SciRhom has secured about EUR 7 million in seed funding from the High-Tech Gruenderfonds (HTGF), HSS and private investors.
For further information, please visit www.SciRhom.com.
About High-Tech Gruenderfonds (HTGF)
High-Tech Gruenderfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 560 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences. Investors in this public-private partnership include the Federal Ministry for Economic Affairs and Energy, the KfW Capital and further 34 industrial companies. For more Information visit high-tech-gruenderfonds.de.
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report “Best Children’s Hospitals” list (2019-2020). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In addition, HSS will be opening a new facility in Florida in early 2020. In 2018, HSS provided care to 139,000 patients and performed more than 32,000 surgical procedures, and people from all 50 U.S. states and 80 countries travelled to receive care at HSS. There were more than 37,000 pediatric visits to the HSS Lerner Children’s Pavilion for treatment by a team of interdisciplinary experts. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is the world’s leading provider of education on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.
Dr. Jens Ruhe
Phone: +49 89 614 241 230
1. Black R, Rauch CT, Kozlosky CJ, et al. A metalloprotease disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385:729-733.
2. Moss ML, Jin S-LC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature. 1997;385:733-736.
3. McIlwain DR, Lang PA, Maretzky T, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335(6065):229-232.
4. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335(6065):225-228.
5. Blobel CP. ADAMs: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Bio. 2005;6:32-43.
6. Dusterhoft S, Babendreyer A, Giese AA, Flasshove C, Ludwig A. Status update on iRhom and ADAM17: It’s still complicated. Biochim Biophys Acta Mol Cell Res. 2019;1866(10):1567-1583.
7. Blaydon DC, Biancheri P, Di WL, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011;365(16):1502-1508.
8. Issuree PD, Maretzky T, McIlwain DR, et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest. 2013;123(2):928-932.
9. Qing X, Chinenov Y, Redecha P, et al. iRhom2 promotes lupus nephritis through TNF-alpha and EGFR signaling. J Clin Invest. 2018;128(4):1397-1412.
Am Klopferspitz 19
Geschäftsführung: Dr. Jens Ruhe
USt-IdNr.: DE 815 667 124
Dr. Jens Ruhe
– Cell-image: iStock/
SData Protection Notice
Effective Date: November 4, 2019
DATA PROTECTION NOTICE OVERVIEW
This Data Protection Notice (“Notice”) is designed to inform you about how we collect, use, and share your personal data through our website (our “Website”), related applications, products, services, and web-based and mobile applications (collectively, the “Services”) operated by SciRhom GmbH, or when you interact with us online. Privacy laws and regulations in certain countries, including the rights of governmental authorities to access your personal data, may differ from those in the country in which you reside or are located when using SciRhom GmbH’s services. SciRhom GmbH will only transfer personal data to governmental entities when authorized by the laws of the countries in which such transfers of personal data occur.
1. THE CATEGORIES OF INFORMATION WE COLLECT
SciRhom GmbH collects the Information you provide to us, as well as Log Files and Cookies. We also use Google Analytics (through the use of a persistent Cookie) to improve our Website and Services.
Information You Provide to Us
We collect personal data you provide to us in the following instances:
• If you provide us feedback or contact us via email, we will collect your name and email address, as well as any other content included in the email, in order to send you a reply.
• We also collect personal data at such other points on our Website and applications that expressly state that personal data is being collected.
Information Collected Via Technology
When you visit our Website, some information is automatically collected.
• Log Files. We gather certain information automatically and store it in log files. This information includes IP addresses, browser type, Internet service provider (“ISP”) data, referring/exit pages, operating system, date/time stamp, and clickstream data. We use this information for purposes including analyzing trends, Website administration, tracking users’ movements around the Website and tailoring our Services to our users’ needs. Except as noted in this Notice, we do not link this automatically collected data to other personal data we have collected from you.
2. HOW WE USE THE INFORMATION WE COLLECT
We use, collect, share, and otherwise process personal data for the purposes described in this Notice or as disclosed to you on our Website or in connection with our services. We only collect the minimum amount of personal data needed to perform the specific processing activity for which the personal data was collected.
Performance of the Services
We process your personal data in order to provide the services to you. This includes, for example, using your personal data for:
• operating our Website;
• providing and delivering the products and services you request, including payment processing; or
• sending you related information, including confirmations, invoices, technical notices, updates, security alerts, and support and administrative messages.
We process your personal data based on your consent in order to communicate with you regarding new contests, promotions, rewards, upcoming events, and other news about products and services offered by SciRhom GmbH and our selected partners.
We process your personal data when we have a legitimate interest to do so. This includes, for example, processing your personal data for:
• improving our Website, products, services and the safety and security of our services, websites, and applications including facilitating identification and authentication, for general research and aggregate reporting, customization of website and application customer experiences;
• understanding you and your preferences in order to enhance your experience and enjoyment using our Website, products, and services;
• responding to your comments and questions and providing customer service;
• linking or combining your personal data with other personal data we obtain from third parties without personally identifying you to such third parties in order to help understand your needs and provide you with better service;
• compliance with a judicial or administrative order or in the course of judicial or administrative proceedings;
• protecting the rights and property of SciRhom GmbH and our agents, customers, and third parties including, but not limited to, the right to enforce our agreements, policies, and terms and conditions.
We may create anonymized data records from personal data by excluding information (such as your name) that makes the data personally identifiable to you. We use this anonymized data to analyze request and usage patterns so that we may enhance the content of our products and services and improve Website navigation. SciRhom GmbH reserves the right to use anonymized data for any purpose and disclose anonymized data to third parties in our sole discretion.
We process your personal data for compliance with any legal obligation to which we are subject.
3. INFORMATION WE SHARE
We share your personal data with Service Providers, Public Authorities, and Third Parties only with your Consent. Additionally, we reserve the right to share your personal data when you have consented to the processing and have the ability to unilaterally revoke such consent at any time or have expressly made such personal data public.
• Service Providers, Consultants and Vendors
– performance of contractual obligations in order to provide the services to you;
– serving our legitimate interests and those of third party vendors, consultants, and other service providers
– protecting the personal safety and property of SciRhom GmbH, its customers, or any other third party;
– providing or improving our services and the safety and security of our services, websites, and applications including facilitating identification and authentication, targeted online and offline marketing, for general research and aggregate reporting, customization of website and application customer experiences;
o enabling third parties to perform services on behalf of SciRhom GmbH including, but not limited to, payment processing, research, analytics, and security; or
• Public Authorities, Including Courts and Law Enforcement Agencies
– compliance with a legal obligation or judicial or administrative order or in the course of judicial or administrative proceedings;
– protecting the rights and property of SciRhom GmbH and our agents, customers, and third parties including, but not limited to, the right to enforce our agreements, policies, and terms and conditions;
• Third Parties:
– facilitating the negotiation of any merger, financing, acquisition, or dissolution, transaction, or proceeding involving sale, transfer, divestiture, or disclosure of all, or a portion of our business or assets to another company. In the event of an insolvency, bankruptcy, or receivership, personal data may also be transferred as a business asset. If another entity acquires our company, business, or assets, that entity will possess the personal data collected by us and will assume the rights and obligations regarding your personal data as described in this Notice. SciRhom GmbH will not disclose your personal data to Third Parties without your express, revocable consent except as specified in this Notice.
4. INTERNATIONAL TRANSFERS OF INFORMATION
We do not process your personal data outside the European Economic Area.
5. DPO AND SUPERVISORY AUTHORITY
If you are residing, or located, in an EU Member State, you may also contact your local supervisory authority, the government agency charged with the enforcement of privacy laws, for information about your rights as a data subject and, in certain circumstances, seek redress for violations of your privacy rights.
We delete your personal data which we process based on your consent if you withdraw your consent, or when you request us to remove your personal data in accordance with this Notice. We will retain your personal data when we have a legitimate interest to do so. For example, we may retain your personal data to resolve disputes, enforce our contractual rights or other user agreements, or comply with legal requirements, including (tax) retention obligations; in that event, your personal data will be blocked from use for any other purpose. In any case, SciRhom GmbH will not retain your personal data longer than necessary for the purposes set out in this Notice.
7. YOUR RIGHTS
SciRhom GmbH will at all times honor your right to Access, Correct, Erase, Restrict, Transfer, Object, and Withdraw Consent at any time with respect to your personal data. You may exercise these rights to which you are entitled by contacting us at info@SciRhom.com.
• Request access to your personal data in order to receive a copy of the personal data we hold about you.
• Request correction of the personal data that we hold about you in order to have any incomplete or inaccurate information corrected, though we may need to verify the accuracy of the new information you provide to us.
• Request erasure of your personal data in order to ask us to delete or remove personal data where there is not a good reason or legitimate interest for us to continuing to process it. Note, however, that we may not always be able to comply with your request of erasure for specific legal reasons which will be notified to you, if applicable, at the time of your request. For example, where we have a legal obligation to retain and store your personal data.
• Request restriction of processing of your personal data in order to ask us to suspend the processing of your personal data.
• Request the transfer of your personal data to you or to a third party. We will provide to you, or a third party you have chosen, your personal data in a structured, commonly used, machine-readable format. Note that this right only applies to personal data which you initially provided consent for us to use or where we used the personal data to perform a contract with or provide services to you.
• Object to processing of your personal data where we are relying on a legitimate interest (or those of a third party) and there is something about your particular situation which makes you want to object to processing on this ground as you feel it impacts on your fundamental rights and freedoms. In some cases, we may demonstrate that we have compelling legitimate grounds to process your personal data which override your rights and freedoms. You may, in particular, control the extent to which we market to you and you have the right to request that we stop sending you marketing messages at any time.
• Withdraw consent at any time where we are relying on consent to process your personal data. However, this will not affect the lawfulness of any processing carried out before you withdraw your consent. In particular, you may opt out of receiving promotional emails from us by following the instructions in those emails. If you opt out, we may still send you non-promotional emails, such as emails about our ongoing business relations.
8. CHANGES TO THIS NOTICE
This Notice is subject to occasional revision. Any changes will be effective upon the earlier of thirty (30) calendar days following our dispatch of an email notice to you or thirty (30) calendar days following our posting of notice of the changes on our Website, and will be effective immediately. If we make any material changes in the way we use your personal data, we will notify you by sending you an email to the last email address you provided to us and/or by posting notice of the changes on our Website. These changes will be effective immediately for new users of our Website. Please note that at all times you are responsible for updating your personal data to provide us with your most current email address. In the event that the last email address that you have provided to us is not valid, or for any reason is not capable of delivering to you the notice described above, our dispatch of the email containing such notice will nonetheless constitute effective notice of the changes described in the notice. Continued use of our Website or service, following notice of such changes after such emails are sent shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes.